Houghton PJ - Search Results

1

AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia.

Moradi Manesh D, El-Hoss J, Evans K, Richmond J, Toscan CE, Bracken LS, Hedrick A, Sutton R, Marshall GM, Wilson WR, Kurmasheva RT, Billups C, Houghton PJ, Smith MA, Carol H, Lock RB. Moradi Manesh D, et al. Among authors: houghton pj. Blood. 2015 Sep 3;126(10):1193-202. doi: 10.1182/blood-2014-12-618900. Epub 2015 Jun 26. Blood. 2015. PMID: 26116659 Free PMC article.

2

Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts.

Leggas M, Stewart CF, Woo MH, Fouladi M, Cheshire PJ, Peterson JK, Friedman HS, Billups C, Houghton PJ. Leggas M, et al. Among authors: houghton pj. Clin Cancer Res. 2002 Sep;8(9):3000-7. Clin Cancer Res. 2002. PMID: 12231547

3

Testing of new agents in childhood cancer preclinical models: meeting summary.

Houghton PJ, Adamson PC, Blaney S, Fine HA, Gorlick R, Haber M, Helman L, Hirschfeld S, Hollingshead MG, Israel MA, Lock RB, Maris JM, Merlino G, Patterson W, Reynolds CP, Shannon K, Yu A, Yu J, Smith MA. Houghton PJ, et al. Clin Cancer Res. 2002 Dec;8(12):3646-57. Clin Cancer Res. 2002. PMID: 12473573

4

Enhanced antitumor activity of irofulven in combination with irinotecan in pediatric solid tumor xenograft models.

Woo MH, Peterson JK, Billups C, Liang H, Bjornsti MA, Houghton PJ. Woo MH, et al. Among authors: houghton pj. Cancer Chemother Pharmacol. 2005 May;55(5):411-9. doi: 10.1007/s00280-004-0902-2. Epub 2004 Oct 16. Cancer Chemother Pharmacol. 2005. PMID: 15503024

5

Improved response in high-risk neuroblastoma with protracted topotecan administration using a pharmacokinetically guided dosing approach.

Santana VM, Furman WL, Billups CA, Hoffer F, Davidoff AM, Houghton PJ, Stewart CF. Santana VM, et al. Among authors: houghton pj. J Clin Oncol. 2005 Jun 20;23(18):4039-47. doi: 10.1200/JCO.2005.02.097. J Clin Oncol. 2005. PMID: 15961757 Clinical Trial.

6

The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL.

Teachey DT, Obzut DA, Cooperman J, Fang J, Carroll M, Choi JK, Houghton PJ, Brown VI, Grupp SA. Teachey DT, et al. Among authors: houghton pj. Blood. 2006 Feb 1;107(3):1149-55. doi: 10.1182/blood-2005-05-1935. Epub 2005 Sep 29. Blood. 2006. PMID: 16195324 Free PMC article.

7

In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models.

Peterson JK, Tucker C, Favours E, Cheshire PJ, Creech J, Billups CA, Smykla R, Lee FY, Houghton PJ. Peterson JK, et al. Among authors: houghton pj. Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6950-8. doi: 10.1158/1078-0432.CCR-05-0740. Clin Cancer Res. 2005. PMID: 16203787

8

Developing new agents for the treatment of childhood cancer.

Kurmasheva R, Morton C, Houghton PJ. Kurmasheva R, et al. Among authors: houghton pj. Curr Opin Investig Drugs. 2005 Dec;6(12):1215-27. Curr Opin Investig Drugs. 2005. PMID: 16372407 Review.

9

Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo.

Graham C, Tucker C, Creech J, Favours E, Billups CA, Liu T, Fouladi M, Freeman BB 3rd, Stewart CF, Houghton PJ. Graham C, et al. Among authors: houghton pj. Clin Cancer Res. 2006 Jan 1;12(1):223-34. doi: 10.1158/1078-0432.CCR-05-1225. Clin Cancer Res. 2006. PMID: 16397046

10

IRS-1: auditing the effectiveness of mTOR inhibitors.

Easton JB, Kurmasheva RT, Houghton PJ. Easton JB, et al. Among authors: houghton pj. Cancer Cell. 2006 Mar;9(3):153-5. doi: 10.1016/j.ccr.2006.02.027. Cancer Cell. 2006. PMID: 16530700 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

589 results

Search Page